Opus Genetics Acquires Two Gene Therapy Candidates from Iveric Bio for the Treatment of Inherited Retinal Diseases
- Iveric received $500,000 up front & high single-digit percentage ownership stake in Opus, 2,632,720 shares of series seed preferred stock of Opus, ~$12.8M in development & regulatory milestones, ~$98.9M in sales milestones along with royalties on net sales of the products
- Opus gets the rights to 2 preclinical-stage AAV-based gene therapy products (IC-100 and IC-200) & will lead the global research, development & commercialization of novel gene therapy candidates for BEST1-related inherited retinal diseases & RHO-adRP programs. Iveric gets the rights for future commercialization of gene therapy products for both programs
- The additional IND-enabling studies & filing an IND for BEST1 are expected to be completed in H2’23
Ref: Globenewswire | Image: Opus Genetics
Related News:- Boehringer Ingelheim Entered into a Collaboration and License Agreement with Surrozen to Develop SZN-413 for the Treatment of Retinal Diseases
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].